Tasuku Hiroshige
Overview
Explore the profile of Tasuku Hiroshige including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hiroshige T, Suekane H, Tokunaga T, Uegaki M, Iwashita M, Taura H, et al.
Anticancer Res
. 2025 Jan;
45(2):751-759.
PMID: 39890182
Background/aim: The prognostic significance of prostate-specific antigen (PSA) kinetics in metastatic castration-sensitive prostate cancer (mCSPC) patients treated with upfront therapy remains unclear. This study investigated the correlation between early PSA...
2.
Ueda K, Uemura K, Ito N, Sakai Y, Ohnishi S, Suekane H, et al.
Curr Oncol
. 2024 Apr;
31(4):1701-1712.
PMID: 38668032
Immuno-oncology (IO) combination therapy is the first-line treatment for advanced renal cell carcinoma (RCC). However, biomarkers for predicting the response to IO combination therapy are lacking. Here, we investigated the...
3.
Hiroshige T, Uemura K, Nakamura K, Igawa T
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612936
Male infertility is a significant factor in approximately half of all infertility cases and is marked by a decreased sperm count and motility. A decreased sperm count is caused by...
4.
Uemura K, Togo A, Hiroshige T, Ohta K, Ueda K, Nishihara K, et al.
Prostate
. 2024 Apr;
84(9):866-876.
PMID: 38590054
Background: A few studies have examined the ultrastructure of prostatic neuroendocrine cells (NECs), and no study has focused on their ultrastructure in three dimensions. In this study, three-dimensional ultrastructural analysis...
5.
Kawaguchi Y, Ohta K, Hiroshige T, Uemura K, Togo A, Nakamura K, et al.
Acta Histochem
. 2024 Mar;
126(3):152153.
PMID: 38484443
Epithelial-stromal relationship in the prostate gland is crucial for maintaining homeostasis, including functional differentiation, proliferation, and quiescence. Pathological stromal changes are believed to cause benign prostatic hyperplasia (BPH). The prostate...
6.
Uemura K, Miyazono Y, Hiroshige T, Ohta K, Ueda K, Nishihara K, et al.
Microsc Microanal
. 2023 Sep;
29(2):832-840.
PMID: 37749734
The ultrastructure of the nuclear envelope (NE) and redundant NE (RNE) of the spermatozoon cannot be observed in detail using conventional electron microscopy. Thus, this study aimed to employ transmission...
7.
Uemura K, Miyazono Y, Hiroshige T, Ohta K, Ueda K, Nishihara K, et al.
Microsc Microanal
. 2023 Jul;
29(4):1460-1466.
PMID: 37488820
This study aimed to clarify the three-dimensional ultrastructure of head-side mice spermatozoa mitochondria. Six 13-week-old male C57BL/6 mice were deeply anesthetized, perfused with 2% paraformaldehyde, and placed in 2.5% glutaraldehyde...
8.
Hiroshige T, Ogasawara N, Kumagae H, Ueda K, Chikui K, Uemura K, et al.
In Vivo
. 2023 Apr;
37(3):1266-1274.
PMID: 37103069
Background/aim: Sarcopenia is a syndrome characterized by the progressive and generalized loss of skeletal muscle mass and has been reported to be a poor prognostic factor for taxane-treated castration-resistant prostate...
9.
Ueda K, Ogasawara N, Ito N, Ohnishi S, Suekane H, Kurose H, et al.
J Clin Med
. 2023 Mar;
12(6).
PMID: 36983417
Nivolumab and ipilimumab (NIVO + IPI) is standard therapy for patients with advanced renal cell carcinoma (RCC). Absolute lymphocyte count (ALC) is a valuable prognostic factor in patients with various...
10.
Ueda K, Suekane S, Kurose H, Ito N, Ogasawara N, Hiroshige T, et al.
Anticancer Res
. 2022 Aug;
42(9):4573-4580.
PMID: 36039432
Background/aim: Immuno-oncology (IO) combination therapy has become the standard of treatment for advanced renal cell carcinoma (RCC). In this retrospective study, we compared the efficacy of first-line molecular targeted therapy...